

**CURRICULUM VITAE
HINA KHAN, MD**

Business Address: Brown University Health Cancer Institute,
164 Summit Avenue, Fain 3
Providence, RI 02906

Business Phone: 401-793-7126

Business Fax: 401-793-2541

Business Email: hina_khan@brown.edu

EDUCATION

7/2001-3/2007 Jawaharlal Nehru Medical School, Aligarh, India

POSTGRADUATE TRAINING

7/2010-6/2013 Mount Sinai School of Medicine at James J. Peters VA Medical Center, Bronx, New York 10468, Internal Medicine

7/2013-6/2016 Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York 10461, Hematology and Oncology

POSTGRADUATE HONORS AND AWARDS

2021-2023 Robert A. Winn Diversity in Clinical Trials Career Development Award (Cohort 1)
(I was in the initial funded cohort of this initiative to prepare early-clinician researchers to become independent clinical trialists committed to health equity in their research careers and as they develop as mentors).

2024 Medical Honoree Award, American Lung Association's Lung Force Walk, Providence, RI.
(This award honors healthcare professionals with demonstrated experience related to lung cancer screening, prevention, treatment, or research in the state of Rhode Island).

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

2013- American Board of Internal Medicine, Diplomat in Internal Medicine

2016- American Board of Internal Medicine, Diplomat in Medical Oncology

- 2018- American Board of Internal Medicine, Diplomat in Hematology
- 2016- Medical License, State of Rhode Island, # MD15397

ACADEMIC APPOINTMENTS

- 7/2016- Assistant Professor of Medicine, Division of Hematology/Oncology, Warren Alpert Medical School, Brown University, Providence, RI
- 07/2024- Mentor, Doctoring Mentor Program, Warren Alpert Medical School, Brown University, Providence, RI.

HOSPITAL APPOINTMENTS

- 7/2016- Attending Physician, Department of Hematology and Oncology, Brown University Health at The Miriam Hospital, Providence, Rhode Island
- 7/2016- Thoracic Oncologist, Brown University Health, Providence, Rhode Island
- 7/2016- Mentor, Hematology and Oncology fellowship program, Brown University
- 7/2022- Site Director, Thoracic Oncology Multidisciplinary Clinic at Brown University Health at Miriam Hospital, Providence, Rhode Island.
- 4/2023- Director, Multidisciplinary Lung Nodule program, Miriam Hospital, Providence, Rhode Island

HOSPITAL COMMITTEES

- 7/2018-12/2024 Institutional Review Board Committee, Miriam Hospital
- 7/2021-7/2025 Scientific Review & Monitoring Committee, Lifespan Office of Cancer Research, Lifespan Cancer Institute
- 1/2022 The Miriam Gala Organizing Committee
- 5/2023- Cancer Oversight Committee, Lifespan Cancer Institute
- 1/2024- Immunotherapy Toxicity Management Committee, Lifespan Cancer Institute

UNIVERSITY COMMITTEES

7/2017-	Principal Investigator and Member, Brown University Oncology Cooperative Group (BrUOG) Thoracic Committee
7/2018-	Member, The Cancer Therapeutics Group for Thoracic Oncology, Brown-Lifespan Joint Biology Program
7/2018-	Member, Thoracic Malignancies Translational Research Disease Group (TRDG), Legorreta Cancer Center at Brown University, Joint program in Cancer Biology
1/2020-	Member, Scientific Review and Monitoring Committee, Lifespan Cancer Institute and Brown University
7/2020-7/2021	Member, Internal Medicine Residency Selection Committee, Brown Alpert Medical School IM residency program
7/2020-	Member, Hematology-Oncology fellowship Curriculum committee
1/2021-	Member, Data Safety and Monitoring Committee, Brown University Oncology Cooperative Group (BrUOG)
7/2021-	Member, Hematology-Oncology fellowship selection committee, Brown University fellowship program
7/2023-	Mentor and Faculty, Future Generation Cancer Scholars program †
1/2024-	Member, Environmental Carcinogenesis Working Group †
6/2024-	Community Outreach and Engagement liaison to the office of Community Health and Equity †
07/2024-	Doctoring Community Mentor, Warren Alpert Medical School

† *Diversity, Equity, and Inclusion (DEI) activity*

NATIONAL COMMITTEES

7/2019-	Member, American Cancer Society-Cancer Action Network
1/2022-	Regional Leadership Board, Board of Directors, American Lung Association †
5/2024-	New England, Rhode Island Leadership Council, American Cancer Society

MEMBERSHIP IN SOCIETIES

2013-	American Society of Clinical Oncology
	2020- now: Mentor, Annual Meeting Women's Networking Center †
	2020- now: Mentor, Early Career and Trainee Center
2013-	American College of Physicians

2016-	Society for Immunotherapy of Cancer
2016-	International Association for the study of Lung Cancer
2019-	Alliance for Clinical Trials in Oncology
	2019- now: Committee Member: Immuno-Oncology Committee
2020-	CARIS Precision Oncology Alliance
	2020- now: Member: Thoracic Oncology Working Group
4/2020-	COVID-19 and Cancer Consortium (CCC19): An international Registry of Cancer patients with COVID-19 infection †
6/2020-	Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): An International Registry on Thoracic Cancer patients with COVID-19 †
1/2021-	Lung cancer Screening Task Force, member (Rhode Island State) †
1/2022-	Development of MIPS Patient-Reported Outcome Performance Measure (PRO-PM) for Preventive Cancer Screening †
1/2022-	Collaboration for Outcomes using Social Media in Oncology (COSMO)
3/2024-	SWOG Cancer Research Network, DEI Leadership Council and committee †
5/2024-	Thoracic Clinical Trial working group, Hoosier Cancer Research Network

† Diversity, Equity, and Inclusion (DEI) activity

JOURNAL REVIEWER

1/2021-	Reviewer, <i>Frontiers in Oncology</i>
1/2023-	Reviewer, <i>Cancer Medicine</i>
4/2024-	Editorial Board, <i>American Journal of Clinical Oncology</i>
6/2025-	Reviewer, <i>Clinical Lung Cancer</i>

PUBLICATIONS LIST

h-index 20 (Google Scholar, 06/26/2025)

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

<https://www.ncbi.nlm.nih.gov/myncbi/hina.khan.5/bibliography/public/>

1. Suhail M, Suhail MF, **Khan H**. Alterations in antioxidant and pro-oxidant balance in preeclampsia: impact on Erythrocyte Osmotic fragility. *Biochemia Medica* 2008 October, 18 (3): 333-341.

2. Suhail M, Faizul Suhail M, **Khan H**. Role of vitamins C and e in regulating antioxidant and pro-oxidant markers in preeclampsia. *J Clin Biochem Nutr*. 2008 Nov;43(3):210-20. doi: 10.3164/jcbtn.2008067. Epub 2008 Oct 31.
3. Suhail M, Faizul-Suhail M, **Khan H**, Suhail S. Doppler echocardiographic diagnosis of a rare pentalogy of fallot having penta-cardiac anomalies: a case report. *J Clin Med Res*. 2009 Oct;1(4):240-3. doi: 10.4021/jocmr2009.09.1261. Epub 2009 Oct 16.
4. Fleishman SB, **Khan H**, Homel P, Suhail MF, Strebel-Amrhein R, Mohammad F, Mahajan D, Rosenwald V, Guarino MJ, Mirzoyev T, Wozniak TF, Suppiah K. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. *J Clin Oncol*. 2010 Dec 1;28(34):5054-60. doi: 10.1200/JCO.2010.30.3818. Epub 2010 Oct 25.
5. Luthra M, **Khan H**, Suhail MF, Avadhani V. Primary pulmonary leiomyosarcoma-a case report. *Arch Bronconeumol*. 2012 Dec;48(12):476-8. English, Spanish. doi: 10.1016/j.arbres.2012.01.006. Epub 2012 Mar 10.
6. Balasundaram C, Luthra M, Chavalitdhamrong D, Chow J, **Khan H**, Endres PJ. Pancreatoblastoma: a rare tumor still evolving in clinical presentation and histology. *JOP*. 2012 May 10;13(3):301-3.
7. **Khan H**, Vale C, Bhagat T, Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. *Seminars in hematology*. 2013 Jan;50(1):16-37. doi: 10.1053/j.seminhematol.2013.01.001. PMID: 23507481.
8. **Khan H**, Gucalp R, Shapira I. Evolving Concepts: Immunity in Oncology from Targets to Treatments. *J Oncol*. 2015;2015:847383. doi: 10.1155/2015/847383. Epub 2015 Apr 28. PMID: 26060497
9. Assal A, Dong B, **Khan H**, Medavarapu R, Shastri A, Pradhan K, Friedman E, Mantzaris I, Janakiram M, Battini R. Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. *Leukemia & Lymphoma*. 2016 Oct ;57(10):2452-2455.
10. **Khan H**, Anampa J. The Evolving Adjuvant Treatment Landscape in Patients with Early Breast Cancer. Editorial. *Mol Biol* 2016, 5:2 DOI: 10.4172/2168-9547.1000e121.
12. Jia L, Carlo MI, **Khan H**, Nanjangud GJ, Rana S, Cimera R, Zhang Y, Hakimi AA, Verma AK, Al-Ahmadie HA. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. *Modern Pathology*. 2019;32(9):1329-1343.
13. **The COVID-19 and Cancer Consortium authors**. A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance. *Cancer cell*. 2020;38(6):761-766.
14. **The COVID-19 and Cancer Consortium authors**. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *The Lancet*. 2020;395(10241):1907-1918.

15. Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, **Khan H**, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, Unni AM, Homer R, Lockwood WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross DAE, Politi K. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance *EGFR* Mutations. *Cancer Res.* 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19.
16. **The COVID-19 and Cancer Consortium authors.** Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. *Cancer Discov.* 2020 Oct;10(10):1514-1527. doi: 10.1158/2159-8290.CD-20-0941. Epub 2020 Jul 22. PMID: 32699031; PMCID: PMC7541683.
17. Judd J, Abdel Karim N, **Khan H**, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M. Characterization of KRAS mutation subtypes in non–small cell lung cancer. *Molecular cancer therapeutics.* 2021;20(12):2577-2584.
18. **The COVID-19 and Cancer Consortium authors.** Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Annals of oncology.* 2021;32(6):787-800.
19. **The COVID-19 and Cancer Consortium authors.** Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. *JAMA oncology.* 2021;7(8):1167-1175.
20. Tsikala-Vafea M, Belani N, Vieira K, **Khan H**, Farmakiotis D. Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. *International Journal of Infectious Diseases.* 2021;106:142-154.
21. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, **Khan H**, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. *Oncotarget.* 2021 Dec 7;12(25):2449-2458. PMID: 34917263.
22. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, **Khan H**, Liu SV, Ma PC, Nagasaka M. Characterization of MET exon 14 skipping alterations (in NSCLC) and identification of potential therapeutic targets using whole transcriptome sequencing. *JTO Clinical and Research Reports.* 2022;3(9):100381.
23. **The COVID-19 and Cancer Consortium authors.** Racial disparities in COVID-19 outcomes among black and white patients with cancer. *JAMA network open.* 2022;5(3):e224304-e224304. †
24. Elkrief A, Hennessy C, Kuderer NM, Rubinstein SM, Wulff-Burchfield E, Rosovsky RP, Vega-Luna K, Thompson MA, Panagiotou OA, Desai A, Rivera DR, Khaki AR, Tachiki L, Lynch RC, Stratton C, Elias R, Batist G, Kasi A, Shah DP, Bakouny Z, Cabal A, Clement J, Crowell J, Dixon B, Friese CR, Fry SL, Grover P, Gulati S, Gupta S, Hwang C, **Khan H**, Kim SJ, Klein EJ, Labaki C, McKay RR, Nizam A, Pennell NA, Puc M, Schmidt AL, Shahrokni A, Shaya JA, Su CT, Wall S, Williams N, Wise-Draper TM, Mishra S, Grivas P, French B, Warner JL, Wildes TM; COVID-19 and Cancer Consortium. Geriatric risk factors for serious COVID-19 outcomes among older

- adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. *Lancet Healthy Longev.* 2022 Mar;3(3):e143-e152. doi: 10.1016/S2666-7568(22)00009-5. Epub 2022 Feb 14. †
25. Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, **Khan H**, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J; TERA-VOLT study group. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERA-VOLT Analysis. *JTO Clin Res Rep.* 2022 Aug;3(8):100335. doi: 10.1016/j.jtocrr.2022.100335. Epub 2022 May 20. †
 26. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilén MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, **Khan H**, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C, COVID-19 and Cancer Consortium (CCC19). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. *JAMA Netw Open.* 2022 Jan 4;5(1):e2142046.42046. doi: 10.1001/jamanetworkopen.2021.42046. Erratum in: *JAMA Netw Open.* 2022 May 2;5(5):e2217965. †
 27. Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths EA, Gulati S, Gupta S, Hwang C, Jain J, Jani C, Kaltsas A, Kasi A, **Khan H**, Knox N, Koshkin VS, Kwon DH, Labaki C, Lyman GH, McKay RR, McNair C, Nagaraj G, Nakasone ES, Nguyen R, Nonato TK, Olszewski AJ, Panagiotou OA, Puc M, Razavi P, Robilotti EV, Santos-Dutra M, Schmidt AL, Shah DP, Shah SA, Vieira K, Weissmann LB, Wise-Draper TM, Wu U, Wu JT, Choueiri TK, Mishra S, Warner JL, French B, Farmakiotis D. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. *Open Forum Infect Dis.* 2022 Mar; 9(3):ofac037. PMID: 35198648. PMCID: PMC8860152. <https://doi.org/10.1093/ofid/ofac037>. Epub 2022 Feb 14
 28. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, **Khan H**, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Metivier AC, Falchero L, Felipe E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzone F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERA-VOLT study group. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERA-VOLT Registry. *J Thorac Oncol.* 2022 May;17(5):661-674. <https://doi.org/10.1016/j.jtho.2021.12.015>. Epub 2022 Feb 01.

29. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, **Khan H**, Liu SV, Ma PC, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. *JTO Clin Res Rep*. 2022 Sep;3(9):100381. <https://doi.org/10.1016/j.jtocrr.2022.100381>. Epub 2022 Jul 22
30. Ma B, Kamle S, Akosman B, **Khan H**, Lee CM, Lee CG, Elias JA. CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. *Front Immunol*. 2022;13:1056397. PMID: 36618349. PMCID: PMC9812560. <https://doi.org/10.3389/fimmu.2022.1056397>. Epub 2022 Dec 21
31. Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, **Khan H**, Azzoli C, Hofstetter M, Lee CM. Chitinase 3-like-1 (CHI3L1) in the Pathogenesis of Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer. *bioRxiv*. 2023;2023.09. 21.558861; doi: <https://doi.org/10.1101/2023.09.21.558861>
32. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, **Khan H**, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM; COVID-19 and Cancer Consortium. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. *JAMA Oncol*. 2023 Jan 1;9(1):128-134. doi: 10.1001/jamaoncol.2022.5357.
33. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, **Khan H**, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). *Lung Cancer*. 2023 Dec;186:107423. doi: 10.1016/j.lungcan.2023.107423. Epub 2023 Nov 13. †
34. Ullah A, Ahmed A, Yasinza AQK, Lee KT, Khan I, Asif B, Khan I, Tareen B, Kakar K, Andam G, Heneidi S, Khan J, **Khan H**, Karki NR, Del Rivero J, Karim NA. Demographics and Clinicopathologic Profile of Pulmonary Sarcomatoid Carcinoma with Survival Analysis and Genomic Landscape. *Cancers (Basel)*. 2023 Apr 26;15(9):2469. <https://doi.org/10.3390/cancers15092469>. Epub 2023 Apr 26
35. Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshov DB, Egan PC, Fein J, Flora DB, Frieser CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, **Khan H**, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakakis V, Vilar-Compte D,

- Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, Rosovsky RP, COVID-19 and Cancer Consortium. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. *JAMA Oncol.* 2023 Oct 1;9(10):1390-1400. PMID: 37589970. PMCID: PMC10436185. <https://doi.org/10.1001/jamaoncol.2023.2934>
36. Kulkarni AA, Hennessy C, Wilson G, Ramesh V, Hwang C, Awosika J, Bakouny Z, **Khan H**, Vilar-Compte D, McKay R, Jani C, Weissmann L, Griffiths E, Batist G, Bouganin N, Mavromatis B, Bashir B, Nguyen RH, Riess JW, Puc M, Kasi A, Berg S, Castillo DR, Hayes-Lattin B, Hosmer W, Flora D, Mishra S, French B, Warner JL, Lopes G, Peters S, Florez N. Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis. *Clin Lung Cancer.* 2024 Apr 10:S1525-7304(24)00044-5. doi: 10.1016/j.clcc.2024.04.003.
 37. Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, **Khan H**, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee CG, Elias JA. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer. *Transl Oncol.* 2024 Nov;49:102108. Epub 2024 Aug 22. PMID: 39178575; PMCID: PMC11388375.
 38. Nassar A, Kim C, Adeyelu T, Bou-Farhat E, Abushukair H, Rakae M, Matteson K, Lau S, Ocejio A, Ardeshtir-Larijani F, Leal T, Ramalingam S, Alam S, Gray J, J Hicks, Kaldas D, Baena J, Berjaga M, Nana F, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo E, Pancirer D, Das M, Ellis-Caleo T, Cheung J, Lin J, Watson A, Camidge D, Sridhar A, Parikh K, Crowley F, Marron T, Aggarwal V, Ahmed M, Kamya Sankar K, Kawtharany H, Zhang J, Owen D, Mingjia Li M, Nagasaka M, Pinato D, Awosika N, Alhamad K, Puri S, Zaman U, Gupta D, Lau C, **Khan H**, Liauw J, Velazquez A, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Jorge Nieva J, Gilberto LopesG, Patrick Ma P, Hossein Borghaei H, Matthew Lee M, Lauren Young L, Raid Aljumaily R, Haris Mirza H, Kwiatkowski D, Herbst R, Flavell R, Naqash A, and Chiang A. Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma. **Nature Communications, June 2025.**

MANUSCRIPTS IN SUBMISSION

1. **Khan H**, Judd J, Xiu J, Ullah A, Raval G, Ma P, Nieva J, Radovich M, James Oberley M, Kim YS, Mamdani H, Raez L, Vanderwalde A, Halmos B, Borghaei H, Liu S, and Karim N. Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Association with clinical outcomes. *In Submission.* Cancer Research.
(I conceptualized the study, contributed significantly to data review and interpretation, manuscript drafting, revisions and editing).
2. **Khan H**, Saiganesh H, Muthiah A, Ramphal K, Dizon D. Challenges in Lung Cancer Survivorship. *In Submission.* Journal of Thoracic Oncology. Brief reports. †
(I conceptualized the study, analyzed and interpreted the data, contributed significantly to literature review and interpretation, manuscript drafting, revisions and editing)

3. **Khan H**, Saiganesh H, Decarli K, Olszewski A, Azzoli C. Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones. *In Submission*. Cancer Research.
(I conceptualized the study, designed the data cohorts, contributed towards data interpretation, contributed significantly to literature review, manuscript drafting, revisions and editing)
4. **Khan H**, Ramphal K, Motia M, Fhon M, Mudge J, Pacheco C, Safran H, Azzoli C. Disparities in Lung Cancer Screening in an urban Diverse Population and impact of a Community based Navigational Program. *CA: Cancer J. Clin.* †
(I conceptualized the study, designed the study/data cohorts, obtained funding for the study, obtained IRB approval, performed data interpretation, performed the literature review, primarily drafted the manuscript, revisions and editing)

† *Diversity, Equity, and Inclusion (DEI) activity*

OTHER PEER-REVIEWED PUBLICATIONS

1. Faculty Reviewer for First Aid Step 2 CS (book), 6th edition.
2. Faculty Reviewer for First Aid Step 3 (book), 5th edition.
3. Peer Reviewer for the ASCO Educational Book, expert panel 2019.
4. Peer Reviewer, Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting Abstracts, 2019.

BOOKS AND BOOK CHAPTERS

1. Janakiram, M.*, **Khan, H.***, Fineberg, S., Zang, X., Sparano, J.A. (2016). Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer. In: Badve, S., Gökmen-Polar, Y. (eds) *Molecular Pathology of Breast Cancer*. Springer, Cham.
https://doi.org/10.1007/978-3-319-41761-5_12
(As the primary co-author, I outlined and drafted the primary content of the chapter. I contributed significantly towards literature review, manuscript draft, revisions and editing)

MULTICENTER TRIALS

1. **Co-Investigator**. Molecular testing of cancer by integrating Genomic, Transcriptomic and Proteomic analysis.
2. **Co-Investigator**. Biomarkers in Lung cancer: Chitinase 3-Like 1.
3. **Co-Investigator**. Javelin Medley: A Phase 1b/2 open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with advanced malignancies (B9991004)

4. **Principal Investigator.** A phase IB/2 study of Viagenpumatucel-L (HS-110) in Combination with multiple treatment regimens in patients with Non-small cell Lung Cancer (The DURGA trial)
5. **Principal Investigator.** BrUOG-L358: Durvalumab and Consolidation SBRT following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Cancer
(I conceptualized the study, designed the study/data cohorts and drafted the original protocol, obtained philanthropic funding for the study, IRB approval, enrolling patients and performed data interpretation, performed the literature review, drafted the abstract, performed revisions and editing of the final abstract)
6. **Sub-Investigator.** A151216: An Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
7. **Co-Principal Investigator.** BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients with Resectable Stage IB – III Non-Small Cell Lung Cancer: A Phase II Brown University Oncology Research Group Trial
8. **Co-Principal Investigator.** RESOURCE: A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumor
9. **Co-Principal Investigator.** KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression 1% and an STK11 co-mutation.
10. **Principal Investigator.** FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anti-cancer Agents in Participants with Solid Tumors.
(I serve as the Site-Principal investigator for this study and one of the first US sites for the Lung cancer cohort. I am actively participating in the safety review committee meetings, providing critical input into dose-limiting toxicity discussions, early data interpretations, etc).

ABSTRACTS

1. Fleishman S, **Khan H**, Guarino M, Suhail M, Strebel R, Homel P, Rosenwald V, Mirzoyev T, Wozniak T, and Suppiah K. Testosterone levels and quality of life (QoL) in male patients with hormone-independent cancers (HIC).. JCO 28, 9140-9140(2010). DOI:10.1200/jco.2010.28.15_suppl.9140. ASCO Annual meeting 2010, Chicago, IL. *(Presented as Poster)*.
2. **Khan H**, Luthra M, Rafiullah. The Seventh Sickle cell Nephropathy. New York ACP Annual meeting November 2010, Rochester, NY. *(Presented as Poster)*.†

3. **Khan H**, Gupta N, Zhan H. A case of Paroxysmal Nocturnal Hemoglobinuria resembling Thrombotic Thrombocytopenic Purpura: A diagnostic dilemma. ACP Annual Meeting: Internal Medicine April 2012, New Orleans, LA (*Presented as Poster*).
4. **Khan H**, Gamboa E, Varma M. Elevated Factor VIII: A significant but lesser known risk factor for Cerebral Vein Thrombosis. New York ACP Annual meeting August 2012, Albany, NY. (*Presented as Poster*).
5. **Khan H**, Gligich O, Acuna A, Sparano J, Anampa J. Breast Cancer in patients with Human Immunodeficiency Virus (HIV) infection: The Bronx experience. International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies October 2015, NIH, Bethesda, MD. (*Presented as Poster*) †
6. **Khan H**, Grant M, Kim N, Janakiram J. PET-CT in staging Bone Marrow in HIV positive patients with Lymphoma. International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies October 2015, NIH, Bethesda. (*Presented as Poster*) †
7. Raajasekar AKA, Ayyapan S, **Khan H**, Mantzaris I, Janakiram M. Progressive multifocal leukoencephalopathy associated with hematopoietic stem cell transplant (HSCT) has better prognosis than PML associated with monoclonal antibodies or chemotherapy in hematological malignancies: analysis of a case series. *Biology of Blood and Marrow Transplantation*. 2016;22(3):S153-S154. American Society of Blood and Marrow Transplantation Annual meeting 2016 (*Presented as Poster*).
8. **Khan H**, Grant M, Kim N, Janakiram M. Discrepancies in PET-CT for staging bone marrow in HIV positive patients with lymphoma. *JCO* 34, e23126-e23126(2016). DOI:10.1200/JCO.2016.34.15_suppl.e23126. ASCO Annual Meeting 2016, Chicago, IL. (*Presented as Poster*).
9. **Khan H**, Hall J, Hakimi A, Pradhan K, Huang H, Cytryn L, Minniti C, Verma A, and Gartrell B. Genomic complexity and prognosis of renal medullary carcinoma.. *JCO* 34, 1544-1544(2016).DOI:10.1200/JCO.2016.34.15_suppl.1544. ASCO Annual meeting 2016, Chicago, IL, (*Presented as Poster*).
10. Nandikolla A, Wang Y, Shah U, Derman O, Kornblum N, Mantzaris I, Shastri A, **Khan H**, Kim N, Grant M, Braunschweig I, Hilda Y, Verma A, Janakiram M. Cell of Origin by IHC Is Not Prognostic of Overall Survival in HIV Associated DLBCL- Analysis of Clinical Pathological Markers in HIV DLBCL. *Blood*. 128. 1867-1867. 10.1182/blood.V128.22.1867.1867. ASH Annual meeting 2016, San Diego, CA. (*Presented as Poster*). †
11. Shastri A, Teixeira M, Bhattacharyya S, Ramachandra N, Lopez R, Ravipati G, Feld J, Dhar Y, Bhagat TD, Choudhary G, Giricz O, Bartenstein M, Shridharan A, Gordon-Mitchell S, Nwanko G, Pradhan K, Ahmad A, Raghavendran K, Kanna R, **Khan H**, Verma A. Targeting MDS and AML stem cells with AZD-9150 mediated inhibition of STAT3. *Blood*. 2016;128(22):4314. ASH Annual meeting 2016, San Diego, CA. (*Presented as Poster*).

12. Acuna A, Gligich O, **Khan H**, Xue X, Lin J, Sparano J, Anampa J. Time differences in Breast cancer diagnosis among Minorities in a large Referral Academic Center. *Cancer Research* 77 (4 Supplement), Abstract P5-10-05. AACR- SABCS 2016. †
13. Gligich O, Acuna A, **Khan H**, Kim R, Wang D, Sparano J, Anampa J. Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection. *Cancer Res* 15 February 2017; 77 (4 Supplement): P2–07–07. <https://doi.org/10.1158/1538-7445.SABCS16-P2-07-07>. San Antonio Breast Cancer Symposium 2016, San Antonio, TX. (*Presented as Poster*) †
14. Starrett J, Guernet A, **Khan H**, Politi K. Drug sensitivity and allele-specificity of first-line osimertinib resistance in EGFR mutations. AACR-IASLC Joint Conference: Lung Cancer, 2020.
15. Starrett J, Guernet A, Cuomo M, Poels K,I.K. Rosenburgh V, Nagelberg A, Farnsworth D, Price K, **Khan H**, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, Unni A, Homer R, Lockwood W, Michor F, Goldberg S, Lemmon M, Smith P, Cross D, Politi K. Drug Sensitivity and Allele Specificity of First-Line Osimertinib resistance EGFR mutations. *Journal of Thoracic Oncology*, Feb 2020. DOI:<https://doi.org/10.1016/j.jtho.2019.12.097>. World Conference for Lung Cancer (WCLC) 2020, Singapore (*Presented as Poster*).
16. **Khan H**, Saiganesh H, Olszewski A, Azzoli C, Safran H. Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones.. *JCO* 38, 1572-1572(2020). DOI:10.1200/JCO.2020.38.15_suppl.1572. ASCO Annual meeting 2020, Chicago, IL. (*Presented as Poster*) †
17. **Khan H**, Saiganesh H, Olszewski A, Azzoli C, Safran H. Comparison of genomic alterations in lung cancer specimens from high and low radon zones: Search for a genomic fingerprint. *Cancer Res* (2020) 80 (16 Supplement): 2338. <https://doi.org/10.1158/1538-7445.AM2020-2338>. AACR Annual meeting 2020 (meeting held virtually due to the COVID-19 pandemic) †
18. Starrett J, Guernet A, **Khan H**, Politi K. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. American Society of Investigative Pathology, PISA Annual Meeting 2020, (meeting held virtually due to the COVID-19 pandemic).
19. **Khan H**, Saiganesh H, Azzoli C, Khurshid H, Birnbaum A, Dizon D. Current Practice of Lung Cancer Survivorship Care: Is a Care Plan Enough?. *Journal of Thoracic Oncology*, Volume 16, Issue 3, Supplement, 2021, Page S157. <https://doi.org/10.1016/j.jtho.2021.01.184>. Oral Presentation at the World Conference for Lung Cancer 2021 (meeting held virtually due to the COVID-19 pandemic). †
20. Enriquez K, Satyanarayana G, Abidi M, Advani S, Egan P, Elkrief A, French B, Friese C, Clara Hwang C, **Khan H**, Lyman G, McKay R, Nagaraj G, Puc M, Robilotti E, Gupta S, Shah D, Wise-Draper T, Yu P, Farmakiotis D. Concomitant infections in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study.. *JCO* 39, 6561-6561(2021).DOI:10.1200/JCO.2021.39.15_suppl.6561. ASCO Annual Meeting 2021, Chicago, IL. (*Presented as Poster*).

21. Hsu R, Baca Y, Xiu J, Wang R, Bodor J, Kim C, **Khan H**, Mamdani H, Nagasaka M, Puri S, Liu S, Korn WM, Nieva J. Molecular Characterization of Kita-Kyushu Lung Cancer Antigen (KK-LC-1) expressing carcinomas. JCO 39, e21000-e21000(2021). DOI:10.1200/JCO.2021.39.15_suppl.e21000. ASCO Annual Meeting 2021, Chicago, IL (*Presented as Poster*).
22. Muthiah A, Chudasama R, Olszewski A, Saiganesh H, Kurt H, Mingrino J, Garcia-Moliner M, Azzoli CA, Khurshid H, Birnbaum A, **Khan H**. Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations.. JCO 39, e21174-e21174(2021). DOI:10.1200/JCO.2021.39.15_suppl.e21174. ASCO Annual meeting 2021, Chicago, IL. (*Presented as Poster*).
23. El-Deiry WS, Arnoff T, Sahin I, Borghaei H, Subbiah V, **Khan H**, Carneiro BA, Safran H, Graff SL, Dizon DS. A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).. JCO 40, 2630-2630(2022).DOI:10.1200/JCO.2022.40.16_suppl.2630. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
24. Kim Y, Bohlman S, Yin J, Cheng H, Walker P, Dacic S, Kim C, **Khan H**, Liu S, Ma P, Nagasaka M, Reckamp K, Abraham J, Uprety D, and Halmos B. Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS). JCO 40, 9122-9122(2022). DOI:10.1200/JCO.2022.40.16_suppl.9122. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
25. Kulkarni A, Hennessy C, Wilson G, Ramesh V, Hwang C, Awosika J, Bakouny Z, Vilar-Compte D, **Khan H**, McKay R, Jani C, Puc M, Kasi A, Berg S, Castillo D, Hayes-Lattin B, Hosmer W, BlakeFlora D, and Duma N. Smoking and COVID-19 in patients with cancer: Novel analysis from CCC19 registry.. JCO 40, e18766-e18766(2022). DOI:10.1200/JCO.2022.40.16_suppl.e18766. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*). †
26. Mamdani H, Wu S, Morgan E, **Khan H**, Nabhan C, Nieva J, Korn W, Uprety D, Puri S, **Khan H**, Raez L, Borghaei H, Halmos H, Ma P, Lopes G, Liu S, and Azmi A. Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC).. JCO 40, e21149-e21149(2022).DOI:10.1200/JCO.2022.40.16_suppl.e21149. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
27. Muthiah A, Chudasama R, Mingrino J, Olszewski A, Kurt H, Garcia-Moliner M, and **Khan H**. Clinical characteristic and outcomes of KRAS G13 mutant non-small cell lung cancers.. JCO 40, e21017-e21017(2022). DOI:10.1200/JCO.2022.40.16_suppl.e21017. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
28. Muthiah A, Muthiah C, Wei C, **Khan H**. Comparing online engagement and academic impact of lung cancer research: An altmetric attention score and PlumX analysis.. JCO 40, 11044-11044(2022). DOI:10.1200/JCO.2022.40.16_suppl.11044. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
29. Muthiah C, Muthiah A, Wei C, **Khan H**. Characterizing online engagement and academic impact of oncology research during the COVID-19 pandemic.. JCO 40, 11043-11043(2022).

- DOI:10.1200/JCO.2022.40.16_suppl.11043. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
30. Raez LE, Baca Y, Nieva JJ, Mamdani H, Lopes G, Borghaei H, Socinski MA, Nabhan C, Wozniak AJ, Vanderwalde AM, Uribe C, **Khan H**, Liu S, Nagasaka M. Acquired EGFR-resistant mutations in non-small cell lung cancer (NSCLC). JCO 40, 9113-9113(2022). DOI:10.1200/JCO.2022.40.16_suppl.9113. ASCO Annual meeting 2022, Chicago, IL. (*Presented as Poster*).
 31. Kulkarni A, Hennessy C, Wilson G, Ramesh V, Hwang C, Awosika J, Bkouny Z, **Khan H**, Vilar D, McKay R, Jani C, Puc M, Kari A, Berg S, Castillo D, Hayes B, Hosmer W, Flora D, French B, Mishra S, Warner J, Lopes G, Peters S, Duma N. Impact of systemic anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: CCC19 registry analysis (Oral presentation). J Thorac Oncol. 2022 Sep; 17(9): S19–S20. Published online 2022 Sep 8. doi: 10.1016/j.jtho.2022.07.038. World Conference for Lung Cancer (WCLC) 2022, Vienna, Austria (*Presented as Poster*).
 32. Raez L, Baca Y, Nagasaka M, Nieva J, Mandani H, Wanderwalde A, Borghaei H, Naban C, Langer C, Socinsky M, Lope G, **Khan H**, Wozniak A, Carracedo C, Liu S. Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, Volume 17, Issue 9, Supplement, 2022, Page S597. <https://doi.org/10.1016/j.jtho.2022.07.1082>. World Conference for Lung Cancer (WCLC) 2022, Vienna, Austria (*Presented as Poster*).
 33. Bakouny Z, Grover P, Labak Ci, Awosika J, Gulati S, Hsu C, Bilen M, Eton O, Fecher L, Hwang C, **Khan H**, McKay R, Ruiz E, Weissmann L, Thompson M, Shah D, Warner J, Shyr Y, Choueiri T, Wise-Draper T. Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer. Annals of Oncology, S772-S773, Sep 2022. ESMO Congress 2022, Paris, France (*Presented as Poster*).
 34. El-Deiry W, Graff S, Azzoli C, Dizon D, Fenton MA, Sikov W, Safran H, **Khan H**, Khurshid H, Schumacher A, Zhou L, Zhao S, Seyhan A, Ryspayeva D, Wood R, Winer A, Calleja E, and Eric A. BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).. JCO 41, TPS3167-TPS3167(2023). DOI:10.1200/JCO.2023.41.16_suppl.TPS3167. ASCO Annual meeting 2023, Chicago, IL. (*Presented as Poster*).
 35. **Khan H**, Judd J, Xiu J, Ullah A, Raval G, Ma P, Nieva J, Radovich M, James Oberley M, Kim YS, Mamdani H, Raez L, Vanderwalde A, Halmos B, Borghaei H, Liu S, and Karim N. Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes. JCO 41, 9038-9038(2023). DOI:10.1200/JCO.2023.41.16_suppl.9038. ASCO Annual meeting 2023, Chicago, IL. (*Presented as Poster*).
 36. **Khan H**, Ramphal K, Motia M, Fhon M, Mudge J, Pacheco C, Safran H, Azzoli CA. Disparities in lung cancer screening in a diverse urban population and the impact of a community-based

navigational program. JCO 41, 6555-6555(2023).

DOI:10.1200/JCO.2023.41.16_suppl.6555. 2023 ASCO Annual meeting, Chicago, IL. (*Presented as Poster*). †

37. Zhang J, Huang C, **Khan H**, Dai Q, Satelli D, Gan G, Phadnis M, Zhong C. MicroDurva: A Prospective Study to Investigate the Role of Microbiome in Predicting the AEs from Durvalumab in Post-CCRT NSCLC Patients. VOLUME 18, ISSUE 11, Supplement , S589-S590, November 2023. DOI:<https://doi.org/10.1016/j.jtho.2023.09.1108>. World Conference for Lung Cancer (WCLC) 2023, Singapore. (*Presented as Poster*).
38. **Khan H**, Ramphal K, Motia M, Fhon M, Mudge J, Yattaw DA, Pacheco C, Safran H, Azzoli C. Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population. VOLUME 18, ISSUE 11, SUPPLEMENT , S468-S469, NOVEMBER 2023. DOI:<https://doi.org/10.1016/j.jtho.2023.09.864>. World Conference for Lung Cancer (WCLC) 2023, Singapore. (*Presented as Poster*). †
39. DiPetrillo T, Garcia-Moliner M, Koffer P, Hepel J, **Khan H**, Khurshid H, Abbas A, Birnbaum A, Olszewski A, Ferreira C, Hassinger F, McCormick M, Giesing H, Rodrigues N, Rosati V, Wood R, Webber A, Maleki S, Azzoli C. Neo Rad (Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi + nivo) with low-dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB – III non-small cell lung cancer (NSCLC). J Clin Oncol 42, 2024 (suppl 16, abstract 20081). 2024 ASCO Annual Meeting, Chicago, IL. (*Presented as Poster*).
40. Kaplan DM, Kareff S, Gandhi N, Elliott A, Magistri M, Sumarriva D, VanderWalde A, Salazar A, Ma P, Halmos B, Olazagasti C, Lopes G, **Khan H**, Rodriguez E. The genomic, transcriptomic, and immunological profile of patients with recurrent/refractory NSCLC. J Clin Oncol 42, 2024 (suppl 16; abstr 8039). 2024 ASCO Annual Meeting, Chicago, IL. (*Presented as Poster*).
41. Koffer P, Mistry H, Hepel J, Dipetrillo T, Wood R, Rosati V, Birnbaum A, Azzoli C, Khurshid H, **Khan H**. Durvalumab and consolidation SBRT following chemoradiation for stage III non-small cell lung cancer: A single institution pilot study. NCT03589547. J Clin Oncol 42, 2024 (suppl 16; abstr e20085). 2024 ASCO Annual Meeting, Chicago, IL. (*Online abstract*).
42. Lee M, Adeyelu T, Wang S, Elliott A, Vanderwalde A, Villaruz L, **Khan H**, Herzberg B, Kim SY, Ma P, Liu S, Halmos B, Cheng H. Evaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment. J Clin Oncol 42, 2024 (suppl 16; abstr 8567). 2024 ASCO Annual Meeting, Chicago, IL. (*Presented as Poster*).
43. Chandani K, Agrawal S, Patel Y, Raval M, **Khan H**. Racial and Gender Disparities in Immune-Related Adverse Effects: A Nationwide Inpatient Sample database analysis. Accepted for poster presentation at WCLC 2024, San Diego, CA (*Presented as Poster*). †
44. Chandani K, Agrawal S, Raval M, **Khan H**. Major Cardiovascular and Cerebrovascular Events in Lung cancer - A Nationwide Inpatient Sample database analysis. Journal of Thoracic Oncology 19 (10), supplement, 293-294, October 2024, WCLC 2024, San Diego, CA (*Presented as Poster*). †

45. Judd J, Gandhi N, Xiu J, Deneka A, **Khan H**, Karim N, Liu S, Naqash A, Borghaei H, Golemis E, Hemenway G. Association of NEDD9 Expression and Survival of Patients with KRAS Mutant and STK11 Mutant Non-Small Cell Lung Cancer (KRASMUT/STK11MUT-NSCLC). Journal of Thoracic Oncology 19 (10), supplement, 168-169, October 2024, WCLC 2024, San Diego, USA.
46. Lee M, Adeyelu T, Wang S, Elliott A, Vanderwalde A, Villaruz L, **Khan H**, Herzberg B, Kim S, Ma P, Liu S, Halmos B, Cheng H. Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS). Journal of Thoracic Oncology 19 (10), supplement, 328-329, October 2024, WCLC 2024, San Diego, CA (*Presented as Poster*).
47. Chandani K, Agrawal S, Raval M, **Khan H**. Racial Disparities in immune-related adverse events in patients with lung cancer treated with Immune checkpoint inhibitors. Accepted for Proffered Oral presentation at ESMO Congress 2024 in Barcelona, Spain, Chicago, IL. (*Presented as Oral Presentation*). †
48. **Khan H**, Gandhi N, Kamle S, Ma B, Lee CG, Xiu J, Vanderwalde A, Lopes G, Halmos B, Azzoli C, Elias J. Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC), 2025 ASCO Annual Meeting, Chicago, IL (*Online abstract*).

† Diversity, Equity, and Inclusion (DEI) activity

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA (NON-PEER REVIEWED)

1. “COVID-19 and Thoracic Malignancies. Evolving standards of care”. **Khan H**, Kulkarni AA, Warner JL. IASLC Lung Cancer News. <https://www.ilcn.org/covid-19-and-thoracic-malignancies/>
2. "Lung Cancer Screening Study with **Dr. Khan**". Brown Medicine: 'Moving The Needle' Podcast. Audio Podcast with Brown Medicine, BPI. <https://brownmed.org/needle/> †
3. “Maximizing your ASCO Annual Meeting experience” Webinar, **Khan H**. Healio.com/HemOnc today, <https://www.healio.com/news/hematology-oncology/20220519/video-oncologist-shares-tips-on-how-to-get-the-most-out-of-asco-annual-meeting>.
4. “Brown Medicine Minute: Dangers of Cigarette Smoking with **Dr. Khan**” Audio Podcast with Brown Medicine, BPI. <https://brownmed.org/news/brown-medicine-minute-dangers-of-cigarette-smoking-with-dr-khan/> †

† Diversity, Equity, and Inclusion (DEI) activity

INVITED PRESENTATIONS

REGIONAL

1. Foundations of Human disease: Prostate and Testicular cancer, School of Pharmacy, University of Rhode Island, Narragansett, RI, 3/2017
2. "Chitinase-3 Like1 and Lung cancer"- Thoracic Malignancies Translational Research Disease Group, Joint program in Cancer Biology, Brown University, Providence, RI, 8/2019
3. "Therapeutics: Organoid models in Lung cancer"- Thoracic Malignancies Translational Research Disease Group, Joint program in Cancer Biology, Brown University, Providence, RI, 2/2020
4. "Radon and Lung cancer in Rhode Island"- Thoracic Malignancies Translational Research Disease Group, Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, 9/2020 †
5. "Brown Cancer Center grants: In-vitro Lung cancer models", Joint program in Cancer Biology, Brown University, Providence, RI, 10/2020
6. "COVID-19 and Lung cancer"- Cancer Therapeutics Program Meeting, Joint program in Cancer Biology, Brown University, Providence, RI, 2/2021 †
7. "COVID-19 infection and Solid malignancies"- Oncology Nursing Society Regional Meeting, Providence, RI, 7/2021
8. "Advanced Lung Cancer: ASCO Updates", Best of ASCO 2021, Providence Downtown Marriott, Providence, RI, 10/2021
9. 8th Annual American Cancer Society Cancer Action Network (ACS-CAN) Research Breakfast, Providence, RI, 11/2021 †
10. "Hematology and Oncology Didactic lectures", New York Medical College Internal Medicine Residency program at Landmark Medical Center, RI, 1/2022-1/2023. (Lecture series over a period of time)
11. Expert Advocate for the "Biomarker Testing in Rhode Island" to enable Universal Biomarker Testing for cancer in RI state. Senate bill "2205" (passed)., Rhode Island State House, 6/2022 †
12. "Lung cancer screening: Lifespan grant enables better outreach to underserved communities", TV interview with Barbara Morse. NBC 10 news. <https://turnto10.com/news/local/lung-cancer-screen-lifepsan-grant-underserved-communities-outreach-ct-scan-medical-medicine-community-health-center>. 6/2022 †
13. "Health Fair" Blackstone Valley Community Health: Community Outreach event to increase lung cancer screening awareness, Central Falls, RI, 8/2022 †
14. "Advanced Lung Cancer: ASCO Updates", Best of ASCO 2022, Providence Downtown Marriott, Providence, RI, 10/2022
15. "Research and Health care delivery in Rhode Island" Panelist. 9th Annual American Cancer Society Cancer Action Network (ACS-CAN) Research Breakfast., Providence, RI, 10/2022 †
16. "Lung screening and nodule program opens at The Miriam Hospital", Television interview with Barbara Morse. NBC 10 news. <https://turnto10.com/features/health-landing-page/lung-screening->

module-program-the-miriam-hospital-lifespan-cancer-institute-ct-scan-medical-life-april-12-2023., 4/2023 †

17. “Toll of Tobacco in Rhode Island”, American Lung Association’s Day of Action for a Tobacco-Free Rhode Island, Rhode Island State House, Providence, RI, 4/2023 †
18. “Ask the Expert” A column in the Medicine @ Brown Magazine <https://medicine.at.brown.edu/article/why-are-lung-cancer-screening-rates-so-low-and-what-could-improve-them/> *, Brown University, Providence, RI, 5/2023 †
19. Lung Cancer screening awareness and advocacy at the ALA’s Lung Force Walk, Providence, American Lung Association, Providence, RI, 6/2023 †
20. “Health Fair” at Blackstone Valley Community Health, Blackstone Valley Community Health Care, Community Outreach and engagement for lung cancer screening awareness, Providence, RI, 8/2023 †
21. “Advanced Lung Cancer: ASCO Updates”, Best of ASCO 2023 – Providence, Providence, RI, 9/2023
22. “Defeat Lung Cancer”, American Lung Association’s Community Connections, Providence, RI, 11/2023
23. “Lung cancer epidemiology and Screening”. Cancer Prevention and Survivorship Elective., Providence, RI., 1/2024 †
24. Radon in Lung cancer, Environmental Carcinogenesis Working group meeting, Cancer Biology program at Legoretta Cancer Center at Brown University, Providence, RI, 3/2024 †
25. “Health and Healing” cancer awareness, The Ministers Alliance of Rhode Island, Providence, RI, 5/2024 †
26. “Carcinogenic risks with alcohol consumption”, October 2024. Invited Health Expert, WPRI 12.
27. “Community based Lung Cancer Screening Navigation Program” Faculty speaker, Rhode Island Lung Cancer Screening Roundtable”, Partnership to Reduce Cancer in RI, May 2025, Providence, RI.

NATIONAL

1. Management of Advanced Non-small cell lung cancer with High PDL-1 expression, The American Virtual Conference of Personalized Approach in Management of Patients with Advanced Lung Cancer (PMLC 2022), 04/2022 (national audience, held virtually due to the COVID-19 pandemic)
2. WinC: Women in Cancer webinar series, “Closing Gaps and Breaking Silos: Leveraging Social Media for Professional Development”, 05/2022 (national audience, held virtually due to the COVID-19 pandemic)

3. Disparities in Lung Cancer Screening in Rhode Island, LUNGeVity's Health Equity in action series (virtual due to COVID-19 pandemic), 7/2022 † (national audience, held virtually due to the COVID-19 pandemic)
4. "Optimizing your Lung Cancer care", LUNGeVity International Lung Cancer Survivorship Conference, 7/2022 (national audience, held virtually due to the COVID-19 pandemic)
5. "Lung Neuroendocrine Tumors", Invited North American Neuroendocrine Tumor Society (NANETS), Providence, RI, 5/2024
6. "Importance of HER2 Biomarker Testing across Solid Tumors", Clinical roundtable, *Medscape* Webinar, 10/2024
7. "Controversies in Thoracic Oncology: Evolving role of Trimodality therapy" and panel discussion, Oklahoma Thoracic Oncology Conference, Oklahoma city, 03/2025 (Session chair).
8. "Frontline therapy in EGFRmt lung cancer: More is better" Speaking Faculty and panel discussant, Oklahoma Thoracic Oncology Conference, Oklahoma city, 03/2025.

INTERNATIONAL

1. "Current practice of survivorship care: Is a Care plan enough?" Oral Presentation at the IASLC's World Conference on Lung Cancer Annual meeting, Singapore (international audience, held virtually due to the COVID-19 pandemic), 9/2021
2. Radon and Lung Cancer, IASLC Lung Cancer Considered Podcast, (international audience on the IASLC platform), 8/2022 †
3. "Racial Disparities in immune-related adverse events in patients with lung cancer treated with Immune checkpoint inhibitors", Proffered oral presentation, European Society of Medical Oncology (ESMO) Congress, Barcelona, Spain, 09/2024 †
4. "Pan-RAS inhibitors", International Association for the study of Lung Cancer (IASLC): Targeted Therapies of Lung Cancer meeting, Huntington Beach, CA, 02/2025

† Diversity, Equity, and Inclusion (DEI) activity

GRANTS:

- | | | |
|--|---------------|-----------|
| 1. | 1/2009-1/2024 | \$225,000 |
| <p>The Joan Decotis Foundation
 The Joan Decotis Foundation Grant. Principal Investigator. BrUOG-L358: Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Cancer.
 Role: PI (PI: Hina Khan, MD)</p> | | |

2. 1/2020-1/2021 \$25,000
Legoretta Cancer Center at Brown University.
Cancer Center Pilot Fund Awards, Brown University. Awarded for Cancer Therapeutics: Blocking Anti-Chitinase 3-Like-1 to overcome resistance to immune checkpoint inhibitors in Advanced Non-small cell lung cancer.
Role: PI (PI: Hina Khan, MD)
3. 11/2021-11/2023 \$ 240,000
Robert A. Winn and BMS Foundation
Robert A. Winn Diversity in Clinical Trials CDA grant. Awarded to support A comprehensive program of public education and nodule management to increase Lung Cancer Screening in Underserved Populations of Rhode Island' †
Role: PI (PI: Hina Khan, MD)
4. 4/2026-04/2031
Brown University.
Integrating data sources to re-evaluate the effectiveness of cancer screening when treatment guidelines change and the eligible population changes.
Grant proposal submitted: requested amount ~\$500,000
Role: Co-Investigator (PI: Jon Steingrimsson, Ph D)

† Diversity, Equity, and Inclusion (DEI) activity

CLINICAL and TRANSLATIONAL RESEARCH EXPERIENCE

Includes ongoing clinical trials and projects.

1. Study the tole of testosterone levels on quality of life in a group of diverse male patients with cancers unrelated to androgens. 2009-2010.
2. Exploring the role of IL8/CXCR2 pathway in the pathogenesis of MDS and AML, evaluating the role of a novel humanized IL8 antibody (HuMaxIL8) against MDS and AML stem cells. Verma lab at the Albert Einstein Cancer Research Center, Bronx, NY. 2015-2016.
3. Survival and clinicopathological features of breast cancer patients with HIV infection: A retrospective study at the Montefiore Medical Center. 2016-2017.
5. Tumor SMARCB1 protein expression in renal medullary carcinoma: a morphologic and molecular analysis of 20 cases at the Montefiore Medical Center. 2017.
5. Investigating the role of KRAS mutations and co-mutation patterns in NSCLC outcomes. A retrospective study at the Lifespan Cancer Institute. 2017-2019.
6. Chi311: a biomarker in Lung Cancer: Studying the relationship between circulating levels of Chi311 in patients with lung cancer and clinical response to immune checkpoint inhibitors. Elias lab at Brown University, RI. 2017-

7. Javelin Medley: A Phase 1b/2 open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with advanced malignancies (B9991004). Co-Investigator.
8. COVID-19 Cancer Consortium (CCC-19): An international consortium to study the effect of COVID-19 on cancer population. Multiple projects studying the effect of COVID-19 in the different cancer cohort, effect on outcomes, etc. Site Principal Investigator. 2020-
9. TERA-VOLT: Thoracic cancers and COVID-19 international registry to investigate the effects of COVID-19 infection on the lung cancer population. Site Principal Investigator. 2020-
10. Chi311: understanding its role in modulating tumor micro-environment and effect of TILs populations. Inv-*itro*, mouse models and organoid based experiments. El-Deiry lab at Brown University, RI. 2021-
11. A phase IB/2 study of Viagenpumatucel-L (HS-110) in Combination with multiple treatment regimens in patients with Non-small cell Lung Cancer (The DURGA trial). Principal Investigator.
12. BrUOG-L358: Durvalumab and Consolidation SBRT following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Cancer. Principal Investigator.
13. Identifying a genomic fingerprint of Radon-induced lung cancer. Comparing genomic alterations in tumors from patients residing in high and low Radon zones. Principal Investigator.
14. Alliance A151216: An Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Sub-Investigator.
15. BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients with Resectable Stage IB – III Non-Small Cell Lung Cancer: A Phase II Brown University Oncology Research Group Trial. Co-Principal Investigator.
16. CARIS Precision Oncology Alliance Collaboration: multiple collaborative projects in Oncogene-driven NSCLC. 2019-
17. RESOURCE: A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumor. Co-Principal Investigator.
18. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance *EGFR* Mutations. Project in collaboration with Yale investigators (Politi K and Goldberg S).
19. Molecular testing of cancer by integrating Genomic, Transcriptomic and Proteomic analysis.
20. KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression 1% and an STK11 co-mutation. Co-Principal Investigator.
21. Comparing online engagement and academic impact of landmark NSCLC articles: a study of altmetric attention score and PlumX analysis. 2022-2023.

22. Challenges in Lung Cancer Survivorship: A retrospective study at the Lifespan Cancer Institute. Principal Investigator. 2021-
23. A comprehensive program to develop tailored public education and nodule management approaches to increase Lung Cancer Screening in Underserved Populations of Rhode Island. Principal Investigator. 2021-
24. Comparing clinical outcomes and safety between first-line treatments for advanced large-cell neuroendocrine tumors of the lung. Multi-institutional Large retrospective study in collaboration with Yale (Chiang A, Naqash R). 2023-
25. Retrospective analysis of the Nationwide Inpatient Sample database: studying Racial and Gender Disparities in Immune-Related Adverse Effects. 2024-

UNIVERSITY TEACHING ROLES

- | | |
|---------------|--|
| 7/2016- | Hematology and Oncology core teaching faculty, Hematology and Oncology fellowship program, Brown Alpert Medical school |
| 7/2016- | Hematology and Oncology teaching faculty, fellows inpatient didactics, Hematology and Oncology fellowship program, Brown Alpert Medical school |
| 7/2016- | Hematology- Oncology fellows outpatient clinic preceptor, Hematology and Oncology fellowship program, Brown Alpert Medical school |
| 7/2016- | Internal medicine residents inpatient teaching faculty, Brown-Lifespan Internal Medicine residency |
| 7/2017- | Second site preceptor, Internal medicine residency program |
| 7/2019-6/2020 | Group leader: Hematology small groups, BIOL 3672: IMS IV, Brown Alpert Medical school |

HOSPITAL TEACHING ROLES

- | | |
|---------|---|
| 7/2016- | Miriam Hospital Oncology teaching service attending |
|---------|---|

ADVISING AND MENTORING ROLES

Hematology and Medical Oncology fellows

- | | |
|---------------|--|
| 7/2019-6/2022 | Rani Chudasama, MD
Hematology-Oncology fellow, Brown University-Warren Alpert Medical School,
Project: Clinical characteristic and outcomes of KRAS G13 mutant non-small cell |
|---------------|--|

lung cancers. *ASCO Annual Meeting abstract 2022, Poster presentation, Chicago, IL.*

7/2022- Boris Martinez Recinos, MD
Hematology-Oncology fellow, Brown University-Warren Alpert Medical School,
Project: Mentoring Dr. Martinez in Health Care Disparities research for professional and career development. † *Ongoing work.*

7/2020- Kathryn Decarli, MD
Hematology-Oncology fellow, Brown University-Warren Alpert Medical School,
Project: Comparison of genomic alterations in lung cancer specimens from high and low radon zones: Search for a genomic fingerprint within the CARIS national database. *Manuscript in submission.*

Internal Medicine Residents

7/2018-6/2020 Harish Saiganesh, MD
Internal Medicine resident, Brown University- Warren Alpert Medical School, Clinical Mentor, Second site clinic.
Research mentor.
Projects:
- Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer patients with KRAS mutations. *Poster at ASCO Annual meeting 2021.*
- Genomic alterations in lung cancer specimens from high and low radon zones: Search for a genomic fingerprint. *Poster at AACR Annual meeting 2020.*
- Current practice of survivorship care: Is a Care plan enough? *Oral Presentation at the IASLC Annual meeting 2021*

7/2020-6/2022 Arun Muthiah, MD
Internal Medicine resident, Brown University- Warren Alpert Medical School, Clinical Mentor, Second site clinic.
Research mentor.
Projects:
- Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer patients with KRAS mutations. *Poster at ASCO Annual meeting 2021.*
- Characterizing online engagement and academic impact of oncology research during the COVID-19 pandemic. *Poster at ASCO Annual meeting 2022.*
- Comparing online engagement and academic impact of lung cancer research: An Altmetric Attention Score analysis. *Poster at ASCO Annual meeting 2022.*

7/2022-6/2024 Kristy Ramphal-Corcoran, MD
Internal Medicine resident, Brown University- Warren Alpert Medical School, Clinical Mentor, Second site clinic
Research mentor.

Project: Increasing engagement and awareness of Lung Cancer Screening in the community. Poster at ASCO Annual meeting 2023.

Medical Students

- 1/2023-12/2023 Jessica Yamada, MS
Brown University- Warren Alpert Medical School, Mentor, Clinical Mentorship program. Professional development and career advancement for underrepresented in medicine. † (Now PGYI, University of Chicago)
- 7/2022-7/2023 Javier Cintron, MS
Alabama College of Osteopathic Medicine, Robert A. Winn Clinical Investigator Pipeline Program. Mentor Match program. †
- 7/2024-12/2024 Olivia Fang, MS-3. Brown University- Warren Alpert Medical School, Mentor, Clinical Mentorship program.
- 7/2024-07/2025 Benjamin Zide, MS-1. Brown University- Warren Alpert Medical School, Mentor, Clinical Mentorship program.
Mentoring for clinical research project “Investigating the role of PM 2.5 in Lung Carcinogenesis: geospatial mapping in Rhode island state” ongoing study.

Undergraduate Students

- 1/2023-1/2024 Gerardo Santizo, MS
Undergrad Brown University, RI., Clinical teaching in oncology. Guidance for careers in medicine for underrepresented students discussing pipeline pathways and programs. †
- 5/2023-6/2023 Leah Brill, MS
University of Vermont, VT, Clinical teaching in Thoracic oncology and career guidance for career options in medicine.

High School Students

- 6/2023- Seoanne Almada
Davies Career and Tech Academy High School, Lincoln, RI.
Future Gen Cancer Scholars, Clinical Mentorship program. Preceptor for oncology clinical observership experience for public high school students of ethnic minorities. Participated as an adviser and mentor for underrepresented students; discussing patient care and potential careers in hematology-oncology. †
- 7/2023- Marilyn Elias
Classical High School, Providence, RI.
Future Gen Cancer Scholars, Clinical Mentorship program. †

7/2023- Melany Reyes
Juanita Sanchez Educational Complex High School, Providence, RI.
Future Gen Cancer Scholars, Clinical Mentorship program. †

† *Diversity, Equity, and Inclusion (DEI) activity*